TD Asset Management
MPLT

TD Asset Management’s MapLight Therapeutics MPLT Stock Holding History

TD Asset Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$971K Buy
47,768
+10,808
+29% +$193K ﹤0.01% 1098
2025
Q4 		$649K Buy
+36,960
New +$619K ﹤0.01% 1149

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TD Asset Management's MPLT Position: Q1 2026 in Review

TD Asset Management increased its MapLight Therapeutics (MPLT) stake by 29% in Q1 2026, buying an estimated $193K and bringing the position to 47,768 shares worth $971K. The position accounts for ﹤0.01% of the portfolio, ranked #1098.

TD Asset Management first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • TD Asset Management held 47,768 shares of MapLight Therapeutics worth $971K as of Q1 2026.
  • TD Asset Management bought 10,808 MapLight Therapeutics shares in Q1 2026, an estimated $193K.
  • MapLight Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q1 2026, its #1098 holding.
  • TD Asset Management first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.